| Typicality: | 0.373 |
| Saliency: | 0.289 |
| in people | 9 | location |
| to vaccination | 3 | other |
| with concurrent blockade of inhibitory pathways | 3 | other |
| vaccine → help create → stronger immune response | 8 |
| vaccine → enhance → immune response | 7 |
| vaccine → increase → host immune responses | 4 |
| vaccine → boost → immune response | 3 |
| vaccine → improve → immune response | 3 |
| negative | neutral | positive |
| 0.039 | 0.519 | 0.442 |
| Raw frequency | 25 |
| Normalized frequency | 0.289 |
| Modifier score | 0.500 |
| Perplexity | 55.980 |